MedTrace Logo

Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors

NCT00002470 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-05-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of the cancer cells. Combining interferon alfa with chemotherapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of fluorouracil plus interferon alfa in treating patients who have advanced metastatic carcinoid tumors.

Conditions

Interventions

BIOLOGICAL

recombinant interferon alfa

DRUG

fluorouracil

Sponsors & Collaborators

  • Cancer Biotherapy Research Group

    collaborator OTHER

  • Mid-Atlantic Oncology Program

    lead OTHER

Principal Investigators

  • James D. Ahlgren, MD · George Washington University

  • Robert K. Oldham, MD · Cancer Therapeutics, Incorporated

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1990-09-30
Completion
2004-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002470 on ClinicalTrials.gov